Back to search
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) trials you may qualify forThe study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the tre…
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved…
Up Until now, there is not well acepted treatment for relapsed/refractory (rr) acute myeloid luekemia (AML), which has low complete response and poor survival.…
To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.